Guided by precise biomarker tests, therapeutic vaccines targeting the pathology of neurodegenerative disease could provide solutions to the impending global crisis in dementia. As Dr Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director of AC Immune, describes here, current work is both establishing the targets that those vaccines must address…
List view / Grid view
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
Scientists have discovered drug targets in the neural circuits that encode memories, paving the way for the treatment of brain disorders.
Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
Scientists used a synthetic thyroid hormone in mice to regulate the TREM2 gene implicated in diseases such as Alzheimer’s and Parkinson’s.
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
A version of the FOXO3 gene can protect brain stem cells from stress during ageing, according to a new study.
A team has shown that synthetic molecule LAU-0901 plus aspirin-triggered NPD1 can repair brain damage in an experimental model of stroke.
Researchers have prevented immune cells from attacking myelin in mice, which stopped the progression of multiple sclerosis (MS).
A team fused the peptide somatostatin to a brain transport protein and found it treated memory loss associated with Alzheimer's in mice.